SCHEMBL24101474

SCHEMBL24101474

COc1ccc2c3c(n(C)c2n1)CCN(C1COC1)CC3

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 4/20 0.41
MTNR1A P48039 3/20 0.41
MCHR1 Q99705 3/20 0.41
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
HTR6 P50406 2/20 0.32
PDCD1LG2 Q9BQ51 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
KDM2B Q8NHM5 1/20 0.31
MTOR P42345 2/20 0.31
ATM Q13315 1/20 0.31
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
HTR1F P30939 1/20 0.31
SOS1 Q07889 1/20 0.31
CNR1 P21554 1/20 0.30
KCNH2 Q12809 1/20 0.30
ATR Q13535 1/20 0.30
CREBBP Q92793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24101532 0.84 MCHR1 (0.40) MCHR1SOS1CNR1KCNH2
SCHEMBL24101853 0.82 MTNR1B (0.47) MTNR1BMTNR1AMCHR1DDB1CRBN
SCHEMBL24101666 0.77 MCHR1 (0.38) MCHR1
SCHEMBL30339453 0.77 MCHR1 (0.38) MCHR1
SCHEMBL24101512 0.74 ADORA2A (0.34) PDCD1LG2CD274HTR1DHTR1BHTR1F
SCHEMBL24101502 0.74 HTR2A (0.48) MTNR1BMTNR1AMCHR1
SCHEMBL24101584 0.71 LRRK2 (0.34) MCHR1SOS1KCNH2ATR
SCHEMBL30339427 0.71 LRRK2 (0.34) MCHR1SOS1KCNH2ATR
SCHEMBL24101747 0.65 MCHR1 (0.46) MCHR1HTR6
SCHEMBL24101585 0.63 TLR9 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
EP-4165042-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF Delix Therapeutics, Inc. (US) 2023-04-19 EP disclosed
WO-2021252691-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF GAP43, GRIN2A, GRIN2C MTNR1B 239/4885MTNR1A 282/4885MCHR1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.